Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine
Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine
复制标题
DOI：
10.1097/inf.0000000000003235
复制
发表时间：
2021-10-01
影响因子：
3.6
通讯作者：
Bilavsky, Efraim
中科院分区：
文献类型：
--
作者：
Snapiri, Ori;Danziger, Chen Rosenberg;Bilavsky, Efraim
背景：疫苗在结束2019年冠状病毒病全球流行的努力中至关重要。BNT162b2被批准用于16岁以上青少年的疫苗接种。尽管这一年龄组的预先测试队列相对较小，但系统性不良事件很少。目前这项研究的目的是提高对潜在不良反应的认识。方法：这是一系列接种疫苗后被诊断为心肌炎的患者。通过儿科医生网络收集了以色列3个儿科医疗中心的患者，并收集了有关这些病例的数据。此外，疫苗接种期间的心肌炎发病率与前几年进行了比较。结果：所有患者都是16-18岁的男性，犹太血统，他们在接种疫苗后1-3天开始出现胸痛(平均2.1天)。在7名患者中，有6名患者在第二次注射后出现症状，1名患者在第一次注射后开始出现症状。所有病例都很轻微，没有一例需要心血管或呼吸支持。与前几年相比，接种期间心肌炎的发病率有所上升。结论：本病例系列描述了2019年冠状病毒疫苗接种与青少年心肌炎之间的时间关联。所有病例都是轻微的，尽管只有长期的随访才能揭示这种心脏损伤的真正影响。虽然疫苗接种活动期间心肌炎的发病率似乎有所增加，但应该在更广泛的范围内进行更全面的数据收集。我们希望这份报告将提醒人们报告事件，并允许分析潜在的不良反应。
Background: Vaccines are paramount in the effort to end the coronavirus disease 2019 global epidemic. BNT162b2 is approved for the vaccination of adolescents over 16 years of age. Systemic adverse events were scarce though the pretested cohort of this age group was relatively small. The aim of the current study is to raise awareness for potential adverse reactions. Methods: This is a case series of patients diagnosed with perimyocarditis following vaccination. Patients were compiled from 3 pediatric medical centers in Israel through a network of pediatricians and data regarding those cases was collected. In addition, incidence of perimyocarditis during the vaccination period was compared with previous years. Results: All patients were males 16-18 years old, of Jewish descent, who presented with chest pain that began 1-3 days following vaccination (mean, 2.1 days). In 6 of the 7 patients, symptoms began following the 2nd dose and in 1 patient following the 1st dose. All cases were mild and none required cardiovascular or respiratory support. The incidence of perimyocarditis during the vaccination period was elevated in comparison to previous years. Conclusions: This case series describes a time association between coronavirus disease 2019 vaccine and perimyocarditis in adolescents. All cases were mild, although only long-term follow-up can reveal the true impact of this cardiac injury. While it seems that the incidence of perimyocarditis during the vaccination campaign period is increased, a more comprehensive data collection on a wider scale should be done. We hope this report will serve as a reminder to report events and allow for analysis of potential adverse reactions.